Myasthenia Gravis
Conditions
Interventions
None listed
Sponsors
UCB Japan Co.,Ltd.
The collaborative organization will be as described below. - Department of Neurology, Toho University Ohashi Medical Center - Department of Neurology, Graduate School of Medicine, Chiba University - Department of Neurology, Kindai University, Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria will be as described below. - Having a confirmed diagnosis of MG (ICD-10 code: G70.0) recorded during the selection period - Having at least 180 days baseline period - Having at least one claim with an immunotherapy recorded at or within 90 days after the first MG diagnosis - Being aged 16 years or older at the index date
Exclusion criteria
Exclusion criteria: Exclusion criteria will be as described below. - Having any immunotherapy for longer than 90 days during the baseline period until 90 days before the index date - Having a claim with MG treatment recorded any time until 90 days before the index date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main outcomes are as described below. - Achievement of < 5mg/day oral corticosteroid - Time to achieve < 5mg/day oral corticosteroid - To describe MG treatment patterns in patient subgroups with and without EFT categorized by age groups | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are as described below. - Steroid-related complications, including diabetes mellitus, osteoporosis) - Total number of medical procedures performed after the index date - Percentage change in annual total MG-related costs before and after the index date | — |
Countries
Japan
Contacts
Public ContactKentaro Taki
UCB Japan Co.,Ltd. Medical Affairs Rare Disease, Medical Affairs Japan
Outcome results
None listed